Heritage Wealth Advisors Increases Position in Johnson & Johnson (NYSE:JNJ)

Heritage Wealth Advisors boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 326,628 shares of the company's stock after acquiring an additional 15,778 shares during the period. Johnson & Johnson accounts for about 2.3% of Heritage Wealth Advisors' portfolio, making the stock its 16th biggest position. Heritage Wealth Advisors' holdings in Johnson & Johnson were worth $47,237,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MRP Capital Investments LLC grew its stake in Johnson & Johnson by 4.1% during the fourth quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after buying an additional 65 shares in the last quarter. Syverson Strege & Co boosted its position in shares of Johnson & Johnson by 4.9% during the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after acquiring an additional 65 shares in the last quarter. Werba Rubin Papier Wealth Management increased its stake in Johnson & Johnson by 3.3% in the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company's stock valued at $301,000 after acquiring an additional 66 shares during the last quarter. Denali Advisors LLC raised its position in Johnson & Johnson by 1.3% during the fourth quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock valued at $742,000 after purchasing an additional 67 shares in the last quarter. Finally, Sage Mountain Advisors LLC lifted its stake in Johnson & Johnson by 0.5% during the fourth quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after purchasing an additional 67 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Raymond James lowered their price target on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Leerink Partners reduced their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Finally, StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 25th. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $171.33.

Insiders Place Their Bets

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Up 0.5 %

NYSE JNJ traded up $0.78 during trading hours on Friday, hitting $163.91. 3,195,985 shares of the company's stock were exchanged, compared to its average volume of 7,609,862. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a 50-day simple moving average of $158.35 and a 200 day simple moving average of $156.23. The firm has a market cap of $395.00 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.29 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.